VIENNA, Austria and CUXHAVEN, Germany, February 26 /PRNewswire/ -- EUCODIS Bioscience, a company developing proteins for the chemical industry, and Lohmann Animal Health (LAH), a company developing and marketing products for animal nutrition and animal health, today announced the achievement of a major development milestone in their collaboration agreement relating to the optimization of an undisclosed protein.
EUCODIS Bioscience has completed the development of the prototype protein which is intended to be part of an innovative LAH product. This achievement triggered a milestone payment to EUCODIS Bioscience from LAH. The development project has moved into its final phase, with LAH testing the protein in the field.
“The achievement of this milestone underlines the capacity of EUCODIS Bioscience to develop enzymes and other proteins for different industrial applications”, said Rudy Pandjaitan, PhD, CEO EUCODIS Bioscience. “Together with the upcoming launch of our first commercial enzyme, this achievement further fuels our efforts to aggressively expand our current European focus into the US and Asian markets.”
“We are pleased to work with a development partner such as EUCODIS Bioscience that combines industrial discipline with a versatile and proven technology”, said Dr. Bruno Kaesler, Managing Director of LAH. “Using their protein know-how and development expertise improves the R&D efficiency of LAH and helps us to provide superior products to our customers”.
About Lohmann Animal Health
Lohmann Animal Health (LAH) is a leading provider of feed components and vaccines for farm animals, contributing to a safe food supply. Based in Germany, LAH is active in major markets worldwide, with more than 70 percent of its revenues generated from export sales. The Company has more than 500 employees in Germany and the United States as well as in its subsidiaries and sales offices in over 30 countries.
As European market leader LAH offers a wide variety of proven and innovative products in the Feed Additives segment. They range from amino acids and antioxidants to flavors and colorants to probiotics and enzymes. LAH also offers the entire spectrum of vitamins and provitamins, including beta-carotene, as well as specialties such as L-carnitine and botanicals.
For more information, please visit http://www.lah.de
About EUCODIS Bioscience
EUCODIS Bioscience GmbH develops enzymes and other proteins and related biocatalytic processes that enable the chemical, pharmaceutical and other industries to establish critical manufacturing processes and to generate superior products.
Based on its proven proprietary technology and led by an experienced management team, EUCODIS Bioscience provides products and services that help its customers to improve efficiencies and to meet growing environmental requirements.
The Company commercializes its enzyme expertise and its versatile and powerful technology in development projects with industrial partners. Current partners include industry leaders such as GlaxoSmithKline, Henkel, and Lohmann Animal Health.
The Company was founded in 2007, as a demerger of the “white biotech” business unit of Eucodis GmbH, a company founded in 2004. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.
CONTACT: For more information, Contact Lohmann Animal Health:, Dr. Roland
Boerner, Head of Corporate Communications, Lohmann Animal Health GmbH & Co
KG, Heinz-Lohmann-Strasse 4, D-27472 Cuxhaven, Germany, +49-4721-747 424,
Roland.Boerner@lah.de; Company contact EUCODIS Bioscience:, Rudy
Pandjaitan, PhD, CEO EUCODIS Bioscience, Brunner Strasse 59, A-1230 Vienna,
AUSTRIA, +43-1-86634 9241, office@eucodisbioscience.com; Media contact
EUCODIS Bioscience:, Frank Butschbacher, Investor Relations &
Communications, +43-650-7844940, office@butschbacher.net
